Enzon Pharmaceuticals 8-K 2011
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
Item 8.01 Other Events.
On December 8, 2011, Enzon Pharmaceuticals, Inc. issued a press release announcing that it presented data from a Phase II, open-label study of PEG-SN38 (EZN-2208) in patients with previously treated metastatic breast cancer.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
The following exhibit is furnished herewith:
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.